# Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions

> **NCT01862900** · PHASE1 · COMPLETED · sponsor: **Providence Health & Services** · enrollment: 14 (actual)

## Conditions studied

- Metastatic Breast Cancer
- Lung Metastases
- Liver Metastases

## Interventions

- **BIOLOGICAL:** MEDI6469

## Key facts

- **NCT ID:** NCT01862900
- **Lead sponsor:** Providence Health & Services
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04-27
- **Primary completion:** 2016-05-17
- **Final completion:** 2018-08-15
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2019-03-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01862900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01862900, "Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions". Retrieved via AI Analytics 2026-09-16 from https://api.ai-analytics.org/clinical/NCT01862900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*